Ekwall E, Holmgren E B, Lundbergh P, Svanbom M, Tunevall G
Scand J Infect Dis. 1979;11(2):135-9. doi: 10.3109/inf.1979.11.issue-2.07.
35 males and 23 females with skin and soft tissue infection, lower respiratory tract infection, urinary tract infection or septicemia with known etiology were treated with cefamandole nafate. The patients were to a large extent (30%) alcoholics and/or drug abusers. Cefamandole was given intravenously as 4 daily doses of 1 g in 52 cases and of 2 g in 6 cases for 8 to 16 (mean 10) days. The effect was considered to be good in 40 patients (70%). Adverse reactions, mostly slight and transient, were seen in 22 patients (38%). Peak serum levels varied from 26 to 82 (mean 50) micrograms/ml after 1 g doses and from 68 to 100 micrograms/ml after 2 g. Previous statements of a better in vitro activity of cefamandole than of older cephalosporins against some gram-negative bacilli were corroborated.
35名男性和23名女性患有已知病因的皮肤和软组织感染、下呼吸道感染、尿路感染或败血症，接受了头孢孟多酯钠治疗。这些患者在很大程度上（30%）是酗酒者和/或药物滥用者。52例患者静脉注射头孢孟多，每日4次，每次1g，6例患者每日4次，每次2g，疗程为8至16天（平均10天）。40例患者（70%）疗效良好。22例患者（38%）出现不良反应，大多轻微且短暂。1g剂量后血清峰值水平在26至82μg/ml之间（平均50μg/ml），2g剂量后在68至100μg/ml之间。先前关于头孢孟多在体外对某些革兰氏阴性杆菌的活性优于 older cephalosporins 的说法得到了证实。 （注：这里“older cephalosporins”直译为“较老的头孢菌素”，但在医学语境中可灵活理解为“早期头孢菌素”之类更通顺的表述，不过按照要求未做调整。）
